What is Kainova Therapeutics?
Kainova Therapeutics operates as a clinical-stage biopharmaceutical enterprise dedicated to the development of GPCR-modulating therapies. By focusing on the intersection of immuno-oncology and inflammation, the company seeks to reshape tumor microenvironments and modulate immune responses. Its dual-geography presence in Canada and Europe provides a robust framework for advancing its diverse portfolio of small molecule and antibody-based assets. The company's market position is defined by its commitment to precision medicine and its ability to navigate the high-barrier-to-entry biotech landscape through strategic scientific partnerships.
How much funding has Kainova Therapeutics raised?
Kainova Therapeutics has raised a total of $23.6M across 1 funding round:
Series B
$23.6M
Series B (2026): $23.6M with participation from Turenne Capital, Schroders Capital, adMare BioInnovations, CTI Life Sciences Fund, Panacea Ventures, Investissement Quebec, Seventure Partners, 3B Future Health Fund I & II, and Viva BioInnovator
Key Investors in Kainova Therapeutics
Turenne Capital
Founded in 1999, Turenne Groupe supports companies, startups, SMEs, and mid-sized enterprises in equity financing at every stage of their development across France, specializing in deep tech and health sectors.
Schroders Capital
Schroders Capital is the private markets investment division of Schroders plc, specializing in private equity, real estate, private debt, credit alternatives, and infrastructure.
adMare BioInnovations
adMare BioInnovations is dedicated to advancing Canada's life sciences industry by leveraging scientific and commercial expertise, specialized R&D infrastructure, and seed capital.
What's next for Kainova Therapeutics?
Looking ahead, the strategic deployment of these funds will be directed toward the expansion of clinical trial operations and the optimization of the company's lead therapeutic candidates. As Kainova Therapeutics moves deeper into its development lifecycle, the focus will shift toward achieving key regulatory milestones and validating the efficacy of its GPCR-modulating platform in human subjects. The company is expected to leverage its international network to foster further collaborative research, potentially setting the stage for future licensing agreements or strategic acquisitions as it matures into a late-stage clinical entity.
See full Kainova Therapeutics company page
